ESR1
10 abstracts
Abstract
Association of germline HSD3B1 (c.1100) genotype with tumoral and clinical outcomes in breast and endometrial cancers.Org: University of South Carolina,
Abstract
ESR1 mutations kit performance with SensID ESR1 reference set 1% AF.Org: APIS Assay Technologies Ltd.,
Abstract
Effect of germline mutations on somatic alteration landscapes in BRCA-associated cancers.Org: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Tempus Labs, Inc., University of Minnesota, Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota,
Abstract
ctDNA detection in patients with brain metastases arising from solid tumors.Org: Duke University Medical Center, Department of Biostatistics & Bioinformatics & CALGB Statistical Center, Duke Cancer Institute, Duke University Cancer Institute, Dana-Farber Cancer Institute,
Abstract
The genomic landscape of adolescent and young adult (AYA) malignancies using DNA and RNA-based next generation sequencing.Org: Yale Cancer Center, Yale School of Medicine, New Haven, CT, Tempus Labs, Inc., David Geffen School of Medicine UCLA, Ohio State University Comprehensive Cancer Center,
Abstract
Comprehensive genomic profiling of Taiwanese patients with breast cancer using a novel targeted panel: Preliminary analyses from a prospective triple-negative cohort.Org: Taipei Veterans General Hospital, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,
Abstract
Validation of a 56 gene panel for the detection of somatic variants in metastatic breast cancer.Org: Epic Sciences, Inc.,
Abstract
Commercial next generation sequencing in a real-world cohort of patients with metastatic breast cancer.Org: Renaissance School of Medicine at Stony Brook University, Stony Brook University Hospital - Cancer Center,
Abstract
Comprehensive molecular profiling from liquid and tissue for analysing the somatic mutational landscape in an Indian breast cancer cohort.Org: Fortis Cancer Institute, Sir H N Reliance Foundation Hospital and Research Centre, BALCO Medical Center, Fortis Hospital Mulund, Datar Cancer Genetics,
Abstract
Prognostic value of TP53 mutation status in metastatic triple-negative and hormone receptor-positive breast cancer using cell-free DNA genomic profiling.Org: Mass General Brigham-Salem Hospital, Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Massachusetts General Hospital, Massachusetts General Hospital Cancer Center, Harvard Medical School (HMS), Boston, MA, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY,